

Pharmakologie von Schmerzmitteln für die Praxis

Teil 1: Paracetamol, NSAR und Metamizol

Teil 2: Opioide

Pharmacologie des analgésiques pour la pratique

1ère partie: paracétamol, AINS et métamizole

2e partie: opioïdes

Literatur/Références

- [1] Theiler R, Wyrisch B. Rationale Schmerztherapie-oder doch nicht? Schweiz Med Forum 2012;12:645–51.
- [2] Hänsel A, von Kanel R. Opiattherapie bei chronischen, nicht-tumorbedingten Schmerzerkrankungen: sinnvoll oder unsinnig? Schweiz Med Forum 2012;12:744–9.
- [3] Bertsche T, Mikus G. [Adverse drug reactions and drug interactions in analgesic therapy]. Ther Umsch 2011;68:19–26.
- [4] Hermann M. [Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Praxis (Bern 1994) 2012;101:1309–14.
- [5] Renaud S, Besson M, Cedraschi C, Landmann G, Suter MR, Taub E, et al. Chronische neuropathische Schmerzen. Schweiz Med Forum 2011;47:3–20.
- [6] Aeschlimann A, Buettner UW, Desmeules JA, de Stoutz ND, Eychmüller S, Limacher F, et al. Empfehlungen zur Opioidtherapie chronischer Schmerzen. Teil 1. Schweiz Med Forum 2005;5:1076–82.
- [7] Aeschlimann A, Buettner UW, Desmeules JA, de Stoutz ND, Eychmüller S, Limacher F, et al. Empfehlungen zur Opioidtherapie chronischer Schmerzen. Teil 2. Schweiz Med Forum 2005;5:1107–13.
- [8] Gerber H, Willimann P, Konrad C. Therapie chronischer Schmerzen: Update Teil 2: Opiat-Analgetika, adjuvante Medikamente und Wirkstoffe mit schmerzmodulierender Eigenschaften. Schweiz Med Forum 2013;13:173–8.
- [9] Gerber H, Willimann P, Konrad C. Therapie chronischer Schmerzen: Update Teil 1: Einführung, Einteilung von Schmerzen und Therapie mit Nicht-Opiat-Analgetika. Schweiz Med Forum 2013;13:148–53.
- [10] Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372–80.
- [11] Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690.
- [12] AGS. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–46.

- [13] Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage* 2010;18:476–99.
- [14] McQuay HJ, Moore RA. Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. *Br J Clin Pharmacol* 2007;63:271–8.
- [15] Toms L, McQuay HJ, Derry S, Moore RA. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. *Cochrane Database Syst Rev* 2008:CD004602.
- [16] Norholt SE, Sindet-Pedersen S, Larsen U, Bang U, Ingerslev J, Nielsen O, et al. Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. *Pain* 1996;67:335–43.
- [17] Moore A, Collins S, Carroll D, McQuay H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. *Pain* 1997;70:193–201.
- [18] Smith LA, Moore RA, McQuay HJ, Gavaghan D. Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. *BMC Med Res Methodol* 2001;1:1.
- [19] Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. *Br J Anaesth* 2011;106:292–7.
- [20] Faber K, Rauber-Lüthy C, Kupferschmidt H, Ceschi A. Akute Paracetamol-Intoxikation: Klinik, Diagnostik und Therapie. *Schweiz Med Forum* 2010;10:647–51.
- [21] Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. *JAMA* 2006;296:87–93.
- [22] Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. *JAMA* 1994;272:1845–50.
- [23] Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. *Hepatology* 1995;22:767–73.
- [24] Warner TD, Vojnovic I, Giuliano F, Jimenez R, Bishop-Bailey D, Mitchell JA. Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I₂: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. *J Pharmacol Exp Ther* 2004;310:642–7.
- [25] Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. *FASEB J* 2008;22:383–90.
- [26] Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? *Ann Rheum Dis* 2012;71:20–5.
- [27] Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. *Am J Gastroenterol* 2008;103:872–82.
- [28] Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. *Arthritis Res* 2001;3:98–101.
- [29] Doherty M, Hawkey C, Goulder M, Gibb I, Hill N, Aspley S, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. *Ann Rheum Dis* 2011;70:1534–41.
- [30] Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. *Circulation* 2010;122:1789–96.
- [31] Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. *Hypertension* 2005;46:500–7.
- [32] Gualtierotti R, Zoppi A, Mugellini A, Derosa G, D'Angelo A, Fogari R. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. *Expert Opin Pharmacother* 2013;14:1875–84.
- [33] Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. *Circulation* 2006;113:1578–87.
- [34] Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. *Epidemiology* 2003;14:240–6.
- [35] Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen

- and paracetamol analgesic treatment of osteoarthritis of the knee or hip. *Ann Rheum Dis* 2004;63:1028–34.
- [36] Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. *Cochrane Database Syst Rev* 2006:CD004257.
- [37] Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 1999;340:1888–99.
- [38] Coxib, traditional NTC, Bhala N, Emberson J, Merhi A, Abramson S, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013;382:769–79.
- [39] Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA* 2000;284:1247–55.
- [40] Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, Committee MS. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet* 2007;369:465–73.
- [41] Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. *Semin Arthritis Rheum* 2010;39:294–312.
- [42] Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. *Am J Gastroenterol* 1998;93:2037–46.
- [43] Chan FK. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks. *Nat Clin Pract Gastroenterol Hepatol* 2006;3:563–73.
- [44] Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. *Arch Intern Med* 1993;153:1665–70.
- [45] Mellemkjaer L, Blot WJ, Sorensen HT, Thomassen L, McLaughlin JK, Nielsen GL, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. *Br J Clin Pharmacol* 2002;53:173–81.
- [46] Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. *CMAJ* 2007;177:347–51.
- [47] Vonbach P, Reich R, Moll F, Krahenbuhl S, Ballmer PE, Meier CR. Risk factors for gastrointestinal bleeding: a hospital-based case-control study. *Swiss Med Wkly* 2007;137:705–10.
- [48] Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ* 2006;332:1302–8.
- [49] Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 2011;342:c7086.
- [50] Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. *Circulation* 2004;109:1468–71.
- [51] Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. *Arch Intern Med* 2009;169:141–9.
- [52] Burmester G, Lanasa A, Biasucci L, Hermann M, Lohmander S, Olivieri I, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. *Ann Rheum Dis* 2011;70:818–22.
- [53] Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med* 2001;345:1809–17.
- [54] Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. *Eur J Pharmacol* 2013.
- [55] Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. *Thromb Haemost* 2013;109:825–33.

- [56] Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. *Ann Rheum Dis* 2007;66:764–70.
- [57] Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. *Br J Pharmacol* 2009;157:931–4.
- [58] Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. *J Hypertens* 2009;27:886–93.
- [59] Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. *Arch Intern Med* 2005;165:161–8.
- [60] Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. *N Engl J Med* 1984;310:563–72.
- [61] Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. *Ann Intern Med* 2000;133:1–9.
- [62] Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, Pugliese F, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. *N Engl J Med* 1984;310:279–83.
- [63] Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. *Am J Kidney Dis* 1996;28:S56–62.
- [64] Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. *Drugs* 2003;63:525–34.
- [65] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. *Arch Intern Med* 1998;158:1108–12.
- [66] Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. *Arch Intern Med* 2000;160:777–84.
- [67] Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. *Heart* 2006;92:1610–5.
- [68] Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. *Lancet* 2004;363:1751–6.
- [69] Swissmedic. *Arzneimittelinformation*. Bern: Schweizerisches Heilmittelinstitut, 2013.
- [70] Planas ME, Gay-Escoda C, Bagan JV, Santamaria J, Penarrocha M, Donado M, et al. Oral metamizol (1 g and 2 g) versus ibuprofen and placebo in the treatment of lower third molar surgery pain: randomised double-blind multi-centre study. Cooperative Study Group. *Eur J Clin Pharmacol* 1998;53:405–9.
- [71] Babej-Dolle R, Freytag S, Eckmeyer J, Zerle G, Schinzel S, Schmeider G, et al. Parenteral dipyron versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study. *Int J Clin Pharmacol Ther* 1994;32:204–9.
- [72] Stankov G, Schmieder G, Zerle G, Schinzel S, Brune K. Double-blind study with dipyron versus tramadol and butylscopolamine in acute renal colic pain. *World J Urol* 1994;12:155–61.
- [73] Laird JM, Cervero F. Effects of metamizol on nociceptive responses to stimulation of the ureter and on ureter motility in anaesthetised rats. *Inflamm Res* 1996;45:150–4.
- [74] Hess B. [Medical management of acute renal colic – there is more than hydration and Buscopan(R)...]. *Praxis (Bern 1994)* 2011;100:293–7.
- [75] Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. *Lancet* 1991;337:85–9.
- [76] Bianchi Porro G, Ardizzone S, Petrillo M, Caruso I, Montrone F. Endoscopic assessment of the effects of dipyron (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. *Digestion* 1996;57:186–90.
- [77] Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. *Eur J Gastroenterol Hepatol* 2003;15:173–8.

- [78] Hassan K, Khazim K, Hassan F, Hassan S. Acute kidney injury associated with metamizole sodium ingestion. *Ren Fail* 2011;33:544–7.
- [79] Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. *Arch Intern Med* 2005;165:869–74.
- [80] IAAAS. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. *JAMA* 1986;256:1749–57.
- [81] Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrrone (metamizole). *Eur J Clin Pharmacol* 2002;58:265–74.
- [82] Basak GW, Drozd-Sokolowska J, Wiktor-Jedrzejczak W. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland. *J Int Med Res* 2010;38:1374–80.
- [83] Maj S, Centkowski P. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. *Med Sci Monit* 2004;10:PI93–5.
- [84] Blaser LS, Tramonti A, Egger P, Haschke M, Krahenbuhl S, Raetz-Bravo A. Hematologic safety of metamizol-analysis of pharmacovigilance data. Annual Research Meeting of the Department of Pharmaceutical Sciences 2014. Basel, 10.2.2014: University of Basel 2013.
- [85] Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. *Hemoglobin* 2010;34:291–304.
- [86] Schonhofer P, Offerhaus L, Herxheimer A. Dipyrrone and agranulocytosis: what is the risk? *Lancet* 2003;361:968–9.
- [87] Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009;10:113–30.
- [88] Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. *Gen Hosp Psychiatry* 2009;31:206–19.
- [89] Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. *CMAJ* 2006;174:1589–94.
- [90] Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. *Pain* 2010;150:573–81.
- [91] Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Trivison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. *Neurology* 2002;59:1015–21.
- [92] Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. *JAMA* 2005;293:3043–52.
- [93] Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology* 1998;50:1842–6.
- [94] Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. *Eur J Pain* 2008;12:804–13.
- [95] Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med* 2005;352:1324–34.
- [96] Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. *Eur Neurol* 2009;61:129–37.
- [97] Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc* 2010;85:S3–14.
- [98] Ballantyne JC. Opioids for chronic pain: taking stock. *Pain* 2006;125:3–4.
- [99] Blumenthal S, Min K, Marquardt M, Borgeat A. Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. *Anesth Analg* 2007;105:233–7.
- [100] Pogatzki-Zahn EM, Zahn PK, Sabatowski R, Strumpf M, Wirz S, Wiebalck A, et al. [Use of controlled release opioids in perioperative pain therapy: a standpoint on a new warning advice in the literature on controlled release opioids]. *Schmerz* 2009;23:109–11.
- [101] Weissman DE, Haddox JD. Opioid pseudoaddiction--an iatrogenic syndrome. *Pain* 1989;36:363–6.
- [102] Organization WH. Cancer pain relief. In: Organization WH, editor. With a guide to opioid availability. Geneva: World Health Organization 1996.

- [103] Ballantyne JC, Mao J. Opioid therapy for chronic pain. *N Engl J Med* 2003;349:1943–53.
- [104] Becker WC, O'Connor PG. The safety of opioid analgesics in the elderly: new data raise new concerns: comment on "The comparative safety of opioids for nonmalignant pain in older adults". *Arch Intern Med* 2010;170:1986–8.
- [105] Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. *Arch Intern Med* 2010;170:1979–86.
- [106] Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. *Drug Alcohol Depend* 2006;81:103–7.
- [107] Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* 2009;181:891–6.
- [108] Stannard C. Opioids in the UK: what's the problem? *BMJ* 2013;347:f5108.
- [109] Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. *Clin Pharmacol Ther* 2003;74:102–12.
- [110] Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. *J Opioid Manag* 2009;5:145–51.
- [111] Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. *Expert Opin Investig Drugs* 2011;20:427–39.
- [112] Lowenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. *Expert Opin Pharmacother* 2009;10:531–43.
- [113] Simpson K, Leyendecker P, Hopp M, Muller-Lissner S, Lowenstein O, De Andres J, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. *Curr Med Res Opin* 2008;24:3503–12.
- [114] Hendler N, Cimini C, Ma T, Long D. A comparison of cognitive impairment due to benzodiazepines and to narcotics. *Am J Psychiatry* 1980;137:828–30.
- [115] Hanks GW, Twycross RG. Pain, the physiological antagonist of opioid analgesics. *Lancet* 1984;1:1477–8.
- [116] McCormick GY, White WJ, Zagon IS, Lang CM. Effects of diazepam on arterial blood gas concentrations and pH of adult rats acutely and chronically exposed to methadone. *J Pharmacol Exp Ther* 1984;230:353–9.
- [117] Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. *Toxicol Sci* 2002;65:107–14.
- [118] Fischer B, Rehm J. Deaths related to the use of prescription opioids. *CMAJ* 2009;181:881–2.
- [119] Kintz P. Deaths involving buprenorphine: a compendium of French cases. *Forensic Sci Int* 2001;121:65–9.
- [120] Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. *Addiction* 2004;99:978–88.
- [121] Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. *Br J Anaesth* 2005;94:825–34.
- [122] Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. *Toxicol Sci* 2001;62:148–54.
- [123] Ross JR, Riley J, Taetgemeyer AB, Sato H, Gretton S, du Bois RM, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. *Cancer* 2008;112:1390–403.
- [124] Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Arch Intern Med* 2010;170:1968–76.
- [125] Cami J, Farre M. Drug addiction. *N Engl J Med* 2003;349:975–86.
- [126] Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. *Cochrane Database Syst Rev* 2010:CD006605.

- [127] Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. *Pain Med* 2008;9:444–59.
- [128] Porter J, Jick H. Addiction rare in patients treated with narcotics. *N Engl J Med* 1980;302:123.
- [129] Weisberg D, Stannard C. Lost in translation? Learning from the opioid epidemic in the USA. *Anaesthesia* 2013;68:1215–9.
- [130] Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: Promises and perils. *Pain* 2013.
- [131] Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. *Addiction* 2010;105:1776–82.
- [132] Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. *Clin J Pain* 2008;24:497–508.
- [133] Skala K, Reichl L, Ilias W, Likar R, Groggl-Aringer G, Wallner C, et al. Can we predict addiction to opioid analgesics? A possible tool to estimate the risk of opioid addiction in patients with pain. *Pain Physician* 2013;16:593–601.
- [134] Watson CP, Watt-Watson JH, Chipman ML. Chronic noncancer pain and the long term utility of opioids. *Pain Res Manag* 2004;9:19–24.
- [135] Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. *Science* 1972;178:984–6.
- [136] Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. *Br J Addict* 1991;86:1601–6.
- [137] Hossick KC. Pethidine Addiction. *Can Med Assoc J* 1955;73:914.
- [138] Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. *J Pain Symptom Manage* 2003;26:655–67.
- [139] Chang YP, Compton P. Management of chronic pain with chronic opioid therapy in patients with substance use disorders. *Addict Sci Clin Pract* 2013;8:21.
- [140] Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. *Eur J Pain* 2006;10:423–33.
- [141] Bekkering GE, Soares-Weiser K, Reid K, Kessels AG, Dahan A, Treede RD, et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. *Curr Med Res Opin* 2011;27:1477–91.
- [142] Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. *Eur J Pain* 2009;13:737–43.
- [143] Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. *Support Care Cancer* 2008;16:999–1009.
- [144] Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaelli W, Tombesi P, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. *J Palliat Med* 2008;11:492–501.
- [145] Collier JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. *Eur J Clin Pharmacol* 2009;65:121–39.
- [146] Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. *Br J Clin Pharmacol* 2013;75:60–78.
- [147] Gupta DK, Avram MJ. Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. *Clin Pharmacol Ther* 2012;91:339–43.
- [148] Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. *J Pharmacol Exp Ther* 1987;240:159–66.
- [149] Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanyl. I. Model development. *Anesthesiology* 1997;86:10–23.
- [150] Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. *Pain* 1996;64:357–64.

- [151] Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. *Age Ageing* 1989;18:258–62.
- [152] Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, et al. Interaction of oxycodone and voriconazole—a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects. *Eur J Clin Pharmacol* 2011;67:863–4.
- [153] Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. *Clin Pharmacokinet* 1999;37:17–40.
- [154] Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. *Br J Clin Pharmacol* 1990;29:289–97.
- [155] Charles B, Hardy J, Anderson H, Tapuni A, George R, Norris R. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? *Support Care Cancer* 2013.
- [156] Novick DM, Kreek MJ, Arns PA, Lau LL, Yancovitz SR, Gelb AM. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. *Alcohol Clin Exp Res* 1985;9:349–54.
- [157] Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. *Proc West Pharmacol Soc* 2001;44:83–4.
- [158] Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. *Biopharm Drug Dispos* 1992;13:445–60.
- [159] Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. *Lancet* 1988;2:914–5.
- [160] Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 db1/buf1). *Biochem Biophys Res Commun* 1988;152:411–6.
- [161] Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. *Pharmacogenomics J* 2007;7:257–65.
- [162] Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. *Clin Pharmacol Ther* 2009;85:31–5.
- [163] Somogyi AA, Barratt DT, Collier JK. Pharmacogenetics of opioids. *Clin Pharmacol Ther* 2007;81:429–44.
- [164] Molanaei H, Carrero JJ, Heimbürger O, Nordfors L, Lindholm B, Stenvinkel P, et al. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *Eur J Clin Pharmacol* 2010;66:269–73.
- [165] Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. *Clin Pharmacokinet* 1996;31:410–22.
- [166] Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. *J Pain Palliat Care Pharmacother* 2007;21:5–16.
- [167] Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. *Drugs* 1994;47 Suppl 1:3–7.
- [168] Gardner JS, Blough D, Drinkard CR, Shatin D, Anderson G, Graham D, et al. Tramadol and seizures: a surveillance study in a managed care population. *Pharmacotherapy* 2000;20:1423–31.
- [169] Sansone RA, Sansone LA. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. *Psychiatry (Edgmont)* 2009;6:17–21.
- [170] Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. *J Neuropsychiatry Clin Neurosci* 2012;24:E52.
- [171] Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. *Am J Psychiatry* 2004;161:1129.
- [172] Hagelberg NM, Saarikoski T, Saari TI, Neuvonen M, Neuvonen PJ, Turpeinen M, et al. Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. *Eur J Clin Pharmacol* 2013;69:867–75.
- [173] Wirz S, Wartenberg HC, Wittmann M, Nadstawek J. Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopedic surgery: A prospective, randomized, double-blind investigation. *Pain Clin* 2005;17:367–76.
- [174] Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. *Mol Diagn Ther* 2007;11:171–81.

- [175] Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. *Clin Pharmacol Ther* 2005;77:458–67.
- [176] Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. *Clin Pharmacol Ther* 1996;60:636–44.
- [177] Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. *Anesth Analg* 2006;102:146–50.
- [178] Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. *Clin Pharmacol Ther* 2007;82:41–7.
- [179] Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. *Clin Pharmacol Ther* 2005;77:312–23.
- [180] Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects—the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. *Eur J Clin Pharmacol* 2005;61:257–66.
- [181] Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. *Drugs* 1993;46:313–40.
- [182] Tzschentke TM, Jahnel U, Kogel B, Christoph T, Englberger W, De Vry J, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. *Drugs Today (Barc)* 2009;45:483–96.
- [183] Tzschentke TM, Christoph T, Schroder W, Englberger W, De Vry J, Jahnel U, et al. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. *Schmerz* 2011;25:19–25.
- [184] Xu XS, Etropolski M, Upmalis D, Okamoto A, Lin R, Nandy P. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR. *Pharm Res* 2012;29:2555–64.
- [185] Merker M, Dinges G, Koch T, Kranke P, Morin AM. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. *Schmerz* 2012;26:16–26.
- [186] Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. *Clin Pharmacol Ther* 1990;47:12–9.
- [187] Angst MS, Buhner M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. *Anesthesiology* 2000;92:1473–6.
- [188] Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. *Br J Anaesth* 1989;62:28–32.
- [189] Dubs A, Wiedemeier P, Caduff B. [Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite]. *Dtsch Med Wochenschr* 1999;124:896–8.
- [190] Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. *Br Med J (Clin Res Ed)* 1986;292:1548–9.
- [191] Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. *Clin Pharmacol Ther* 1993;54:158–67.
- [192] Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. *Life Sci* 2001;69:409–20.
- [193] Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. *Clin Exp Pharmacol Physiol* 2000;27:524–8.
- [194] King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. *Palliat Med* 2011;25:525–52.
- [195] Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, et al. *Drug Prescribing in Renal Failure*. Philadelphia, PA, US: American College of Physicians-American Society of Internal Medicine, 1999.
- [196] Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. *Br J Anaesth* 1990;64:276–82.

- [197] Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. *Eur J Pain* 2006;10:743–8.
- [198] Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). *Pain Pract* 2008;8:287–313.
- [199] Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. *Drug Metab Dispos* 1998;26:257–60.
- [200] Kapil RP, Cipriano A, Michels GH, Perrino P, O'Keefe SA, Shet MS, et al. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. *Clin Drug Investig* 2012;32:583–92.
- [201] Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. *Br J Anaesth* 2006;96:627–32.
- [202] Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. *J Support Oncol* 2012;10:209–19.
- [203] Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. *Drug Metab Dispos* 1997;25:1072–80.
- [204] Kokubun H, Ebinuma K, Matoba M, Takayanagi R, Yamada Y, Yago K. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. *J Pain Palliat Care Pharmacother* 2012;26:98–104.
- [205] Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. *Gen Hosp Psychiatry* 2010;32:648 e9– e10.
- [206] Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. *Pharmacotherapy* 1997;17:746–52.
- [207] Bentley JB, Borel JD, Nenad RE, Jr., Gillespie TJ. Age and fentanyl pharmacokinetics. *Anesth Analg* 1982;61:968–71.
- [208] Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. *Br J Anaesth* 2011;107:319–28.
- [209] Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. *J Clin Pharmacol* 1995;35:37–44.
- [210] Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. *Palliat Med* 2001;15:26–34.
- [211] Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. *J Opioid Manag* 2008;4:335–6, 9–44.
- [212] Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. *J Pain Symptom Manage* 1995;10:184–6.
- [213] Durnin C, Hind ID, Wickens MM, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. *Proc West Pharmacol Soc* 2001;44:81–2.
- [214] Paramanandam G, Prommer E, Schwenke DC. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. *J Palliat Med* 2011;14:1029–33.
- [215] Clemens KE, Klaschik E. Morphin und Hydromorphon bei Palliativpatienten mit Niereninsuffizienz. *Anästhesi Intensivmed* 2009;50:70–6.
- [216] Junker U, Figge V. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study]. *MMW Fortschr Med* 2005;147 Suppl 3:91–6.
- [217] Sittig HB. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study]. *MMW Fortschr Med* 2004;146:95–8.
- [218] Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. *Drug Metab Dispos* 2004;32:447–54.

- [219] Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. *Basic Clin Pharmacol Toxicol* 2009;104:335–44.
- [220] Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Eur J Clin Pharmacol* 2011;67:63–71.
- [221] Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. *Br J Clin Pharmacol* 2010;70:78–87.
- [222] Watanabe M, Homma M, Momo K, Okoshi Y, Wada T, Hara A, et al. Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey. *Eur J Clin Pharmacol* 2011;67:859–61.
- [223] Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Clin Pharmacol Ther* 1998;64:603–11.
- [224] Saari TI, Gronlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. *Eur J Clin Pharmacol* 2010;66:387–97.
- [225] Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstrom S, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. *Eur J Clin Pharmacol* 2012;68:55–64.
- [226] Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. *J Clin Anesth* 1996;8:13–8.
- [227] Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. *Drug Metab Dispos* 2004;32:930–6.
- [228] Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. *Am J Ther* 2002;9:53–68.
- [229] Thierry C, Boeynaems JM, Paolo M. Actions of tilidine and nortilidine on cloned opioid receptors. *Eur J Pharmacol* 2005;506:205–8.
- [230] Seiler KU, Jahnchen E, Trenk D, Brennscheidt U, Heintz B. Pharmacokinetics of tilidine in terminal renal failure. *J Clin Pharmacol* 2001;41:79–84.
- [231] Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone--metabolism, pharmacokinetics and interactions. *Pharmacol Res* 2004;50:551–9.
- [232] Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. *Clin Pharmacokinet* 2002;41:1153–93.
- [233] Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. *J Clin Psychopharmacol* 2002;22:211–5.
- [234] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. *Chem Res Toxicol* 1996;9:365–73.
- [235] Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. *Arch Intern Med* 2006;166:1280–7.
- [236] Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004;28:497–504.